BPMX BioPharmX Corporation. Common

0.45
+0.01  (2.27%)
Previous Close 0.44
Open 0.45
Price To book 0.00
Market Cap 30.47M
Shares 67,719,000
Volume 414,647
Short Ratio 1.91
Av. Daily Volume 1,301,260

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated in 2017
BPX-03
Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia
Phase 2b completion of enrollment announced January 4, 2017. Official company guidance is for data due 1H 2017. Estimate is mid-April.
BPX-01
Acne

Latest News

  1. BIOPHARMX CORP Files SEC form 8-K, Change in Directors or Principal Officers
  2. SPIE Photonics West Presentations to Show BioPharmX was First to Visualize Minocycline on the Skin Using Multiphoton Microscopy
  3. BIOPHARMX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
  4. Specialty Pharma Industry Veteran Charles Gregory Vontz Joins BioPharmX Board of Directors
  5. BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
  6. BioPharmX Completes Enrollment of BPX-01 Phase 2b OPAL Clinical Trial for Acne Vulgaris
  7. BIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  8. BIOPHARMX CORP Financials
  9. BioPharmX (BPMX) Exited Fiscal Third Quarter with Strong Balance Sheet
  10. BIOPHARMX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Of
  11. BioPharmX Corporation Reports Third Quarter Financial Results
  12. ETFs with exposure to BioPharmX Corp. : December 13, 2016
  13. These 5 Stocks Under $10 Could Make You a Lot of Money
  14. BioPharmX to present evidence that BPX-01 topical minocycline gel may reduce acne-associated inflammation
  15. BioPharmX to Report Third Quarter Financial Results
  16. BioPharmX Presents Research at Cell Biology 2016 Showing How Molecular Iodine Promotes Breast Health by Attacking Fibrocystic Breast Tissue
  17. BIOPHARMX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  18. BioPharmX Corporation Announces Closing of a $12.5 Million Unit Offering
  19. BIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and
  20. BioPharmX Corporation Announces Pricing of Unit Offering